Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy

Affiliations

¹ Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
² The BENEFIT Kids Community Advisory Board (CAB), Asia Pacific Council of AIDS Service Organizations, Bangkok, Thailand.
³ Global Tuberculosis Community Advisory Board (TB CAB).
⁴ TB Proof, Cape Town, South Africa.
⁵ The BENEFIT Kids Community Advisory Board (CAB), Desmond Tutu TB Centre CAB, Cape Town, South Africa.
⁶ The BENEFIT Kids Community Advisory Board (CAB), Global Coalition of TB Advocates.
⁷ Touched by TB, National Coalition of People Affected by TB, India.
⁸ Treatment Action Group, New York, NY.
⁹ TB Alliance, New York, NY, USA.
¹⁰ The BENEFIT Kids Community Advisory Board (CAB), TB Proof, Cape Town, South Africa.

Editorial

L Viljoen et al. Int J Tuberc Lung Dis. 2023.

. 2023 Sep 1;27(9):655-657.

doi: 10.5588/ijtld.23.0164.

¹ Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
² The BENEFIT Kids Community Advisory Board (CAB), Asia Pacific Council of AIDS Service Organizations, Bangkok, Thailand.
³ Global Tuberculosis Community Advisory Board (TB CAB).
⁴ TB Proof, Cape Town, South Africa.
⁵ The BENEFIT Kids Community Advisory Board (CAB), Desmond Tutu TB Centre CAB, Cape Town, South Africa.
⁶ The BENEFIT Kids Community Advisory Board (CAB), Global Coalition of TB Advocates.
⁷ Touched by TB, National Coalition of People Affected by TB, India.
⁸ Treatment Action Group, New York, NY.
⁹ TB Alliance, New York, NY, USA.
¹⁰ The BENEFIT Kids Community Advisory Board (CAB), TB Proof, Cape Town, South Africa.

No abstract available

Conflict of interest statement

Conflicts of interest: none declared.

1. World Health Organization WHO consolidated guidelines on tuberculosis: Module 5: management of tuberculosis in children and adolescents. Geneva, Switzerland: WHO; 2022. - PubMed
1. World Health Organisation TB/HIV and multidrug/rifampicin-resistant TB (MDR/RR-TB), 2021–2025. Geneva, Switzerland: WHO; WHO global lists of high burden countries for tuberculosis (TB), p. 2021.
1. Monedero-Recuero I, et al. Situational analysis of 10 countries with a high burden of drug-resistant tuberculosis 2 years post-UNHLM declaration: progress and setbacks in a changing landscape. Int J Infect Dis. 2021;108:557–567. - PubMed
1. Alffenaar JWC, Marais BJ, Touw DJ. Paediatric formulations for the treatment of drug resistant TB: closing the gaps. Int J Tuberc Lung Dis. 2022;26(12):1097–1100. - PMC - PubMed
1. Treatment Action Group 2022 report on TB research funding trends. New York, NY, USA: TAG; 2022.